Invention Application
- Patent Title: CROSS-LINKED NUCLEOSIDE AND NUCLEOTIDE USING SAME
-
Application No.: US17800339Application Date: 2021-02-17
-
Publication No.: US20230124641A1Publication Date: 2023-04-20
- Inventor: Satoshi OBIKA , Takao YAMAGUCHI , Yota SAKURAI , Chika YAMAMOTO , Kei SUGITA , Takao INOUE , Tokuyuki YOSHIDA
- Applicant: Osaka University , Japan as Represented by Director General of National Institute of health Sciences
- Applicant Address: JP Osaka; JP Kawasaki-sjo, Kanagawa
- Assignee: Osaka University,Japan as Represented by Director General of National Institute of health Sciences
- Current Assignee: Osaka University,Japan as Represented by Director General of National Institute of health Sciences
- Current Assignee Address: JP Osaka; JP Kawasaki-sjo, Kanagawa
- Priority: JP2020-025726 20200218
- International Application: PCT/JP2021/006017 WO 20210217
- Main IPC: C07D493/08
- IPC: C07D493/08 ; C07H21/04 ; C07D239/10
Abstract:
A cross-linked nucleoside of the present invention is a compound represented by the formula (I) below. The cross-linked nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The cross-linked nucleoside also has excellent industrial productivity.
Information query
